• sign in
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Aging
  • Alzheimer's disease
  • Artificial intelligence
  • Biosimilars
  • China CAR T
  • Coronavirus
  • Infographics: Dynamic digital data analysis
  • Israel
  • IVDs on the rise
  • Radiopharmaceuticals
  • Rise of obesity
  • Top Biopharma Trends of 2023
  • Top Med-tech Trends of 2023
  • Top Preclinical Trends of 2023
  • Premium reports
  • Premium reports
  • BioWorld Financings Reports
  • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Aging
    • Alzheimer's disease
    • Artificial intelligence
    • Biosimilars
    • China CAR T
    • Coronavirus
    • Infographics: Dynamic digital data analysis
    • Israel
    • IVDs on the rise
    • Radiopharmaceuticals
    • Rise of obesity
    • Top Biopharma Trends of 2023
    • Top Med-tech Trends of 2023
    • Top Preclinical Trends of 2023
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
Breaking News: BioWorld celebrates nine wins at 2024 APEX AwardsSee today's BioWorld Science
Home » Rome Therapeutics divulges new L1RE1 and HERV-K reverse transcriptase inhibitors
X
/images/Cortellis_Flagship_Logo_TM_RGB_Color.png

Upgrade your daily dose of biopharma and medtech news

Subscribe to BioWorld™ news services

See subscription options
To read the full story, subscribe or sign in.
Infection

Rome Therapeutics divulges new L1RE1 and HERV-K reverse transcriptase inhibitors

June 5, 2024
No Comments
Rome Therapeutics Inc. has synthesized 4’-halomethyl-cytidine phosphoramidate compounds acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase inhibitors reported to be useful for the treatment of viral infections, cancer, inflammation, neurodegeneration and immunological disorders.
BioWorld Science Infection Patents

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for August 2, 2024.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for August 2, 2024.
  • Ocaliva

    PBC patients fight back in Europe on looming Ocaliva withdrawal

    BioWorld
    Those affected by primary biliary cholangitis (PBC) are fighting back against the recommendation by the EMA that the marketing authorization for Ocaliva...
  • Illustration of herpes simplex virus particles

    Long-acting helicase-primase inhibitor prevents HSV recurrences

    BioWorld Science
    Half of the individuals with genital herpes simplex virus (HSV) infection experience several recurrence episodes per year, especially if the causative agent is...
  • Syringe with illustration of molecules

    Working backward from the goal is promising HIV vaccine strategy

    BioWorld Science
    Last week, the 2024 meeting of the International AIDS Society (IAS) was wrapping up as the 2024 Olympic Games were about to begin. That timing was probably what...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Aging
    • Alzheimer's disease
    • Artificial intelligence
    • Biosimilars
    • China CAR T
    • Coronavirus
    • Infographics: Dynamic digital data analysis
    • Israel
    • IVDs on the rise
    • Radiopharmaceuticals
    • Rise of obesity
    • Top Biopharma Trends of 2023
    • Top Med-tech Trends of 2023
    • Top Preclinical Trends of 2023
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
We use necessary cookies to make our site work. If you allow, we use optional cookies to measure our site’s performance, personalize content and ads to you, and provide social media features.Learn more
Company Logo

Cookie Preference Center

  • Your preferences

  • Strictly Necessary Cookies

  • Functional Cookies

  • Targeting Cookies

  • Social Media Cookies

  • Performance Cookies

Your preferences

As described in our Corporate Privacy Notice and Cookie Policy, we use cookies (including pixels or other similar technologies) on our websites, mobile applications and related products (the “services”). The types of cookies we use are described below.​

Strictly Necessary Cookies

Always Active

These are cookies necessary for the services to function and are always active. They are usually only set in response to actions made by the user which amount to a request for services, such as setting privacy preferences, logging in, or filling in forms. ​

Functional Cookies

These cookies enable the services to provide enhanced functionality and personalization. They may be set by us or by third party providers we use to provide the services. If you do not allow these cookies to run, then the services may not function properly.​

Targeting Cookies

These cookies may be set through the services by our advertising partners to learn about your interests and present you with relevant advertisements on other sites. These advertising partners may be able to identify you based on your device or other online activity.​

Social Media Cookies

These cookies are used to enable social media sharing or “like” buttons on our services. They also provide the ability to link your account or engage with our content on or through a social media platform such as Facebook, Twitter or LinkedIn. These cookies may enable such platforms to track your online activity and interests. ​

Performance Cookies

These cookies count visits and traffic sources in order to measure and improve the performance of the services. They help identify which pages or functions within the services are the most and least popular and see how visitors move around our services.​

Cookie List

Consent Leg.Interest
label
label
label
label
Powered by Onetrust